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estimates. Results: Treatment with pegylated interferon alfa-2a was associated 
with lower total costs. The estimated budget savings varied from 20,907.97 RUB 
to 104,366.07 RUB per one patient. CERs for pegylated interferon alfa-2a were 
less than that for pegylated interferon alfa-2b in all patient subgroups. The low-
est CER was observed for patients with genotype 2 received pegylated interferon 
alfa-2a (240,789.70 RUB per one patient with SVR) and the highest CER – for cir-
rhotic patients with genotype 1 received pegylated interferon alfa-2b (1,879,694.72 
RUB per one patient with SVR). The analysis of the IRDU showed, that inefficient 
budget expenses associated with pegylated interferon alfa-2b treatment may reach 
58,770.84 RUB per one patient infected with HCV-genotypes 1/4. SAs demonstrated 
that results were robust to changes in the drug costs. ConClusions: The present 
study has demonstrated that administration of pegylated interferon alfa-2a has 
the better pharmacoeconomic profile in the treatment of Russian patients with 
chronic hepatitis C.
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objeCtives: To estimate the cost of treatment discontinuation due to label stopping 
(futility) rules of telaprevir (TVR) and boceprevir (BOC) triple therapy in Brazilian 
public (SUS) and private health care system (SS). Methods: Treatment costs con-
sidered drug acquisition costs from a public and private payer perspective in Brazil. 
Stopping rules (SR) were defined according to the label of each drug. For TVR the SR 
were defined at week4 (SR WK4) and at week 12 (SR WK12) as viral load (VL) > 1.000 
IU/ML. For BOC, SR were defined at week 12 (SR WK12) as VL > 100 UI/mL and at week 
24 (SR WK24) as detectable VL. Patients eligible for the SR were gathered for naïve 
and experienced patients from the respective phase 3 trials. As data for SR WK24 
was not published for BOC in naïve patients it was assumed to be the same as SR 
WK12 and a deterministic sensitivity analysis was carried out. Results: Under 
the SUS perspective, the average cost of naïve patients interrupting treatment with 
TVR was R$ 670 compared to an average cost of R$ 3.396 per interrupted treatment 
with BOC, and for treatment experienced patients, TVR had an average cost of R$ 
352 compared to an average cost of R$ 3.041 for BOC per patient meeting the SR. 
Under the SS perspective, TVR had an average cost of R$ 1.433 per interrupted naïve 
treatment and R$ 753 per interrupted treatment in experienced patients and BOC 
had an average treatment cost of R$ 8.305 per naïve patient interrupting treatment 
and R$ 4.753 per interrupted treatment in experienced patients. ConClusions: 
BOC had higher costs associated with treatment futility when compared to TVR, 
especially in treatment experienced patients, in both the public and private health 
care systems in Brazil.
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objeCtives: Currently, 23 thousand people (registered) are suffering from Hepatitis 
C in Germany (more 60% genotype 1). TThe licensing of direct-acting antivirals 
heralds a new era in the treatment of hepatitis C virus (HCV) genotype 1. Clinical 
studies showed a significant increase in sustained virological response rates from 
38-46% to 63-79%. This study was to evaluate the cost-effectiveness of newly intro-
duced triple therapy with Telaprevir (TVR+PR) compared to dual therapy (PR) for the 
treatment of genotype 1 hepatitis C virus (HCV) infection in previously untreated 
patients. Methods: A systematic literature review identified relevant studies. A 
Bayesian mixed treatment comparison model was fitted for each patient popu-
lation. Previously published economic Markov model comparing triple therapy 
(TVR + PR) and dual therapy (PR) has been adjusted for the Kazakhstan context of 
health care (payer perspective). Clinical outcomes and dose were taken from the 
phase ADVANCE-3 trial. Other parameters of the model - including utilities - were 
adapted from Kazakhstan or if not available from the international literature after 
an extensive search of the literature. Drug costs were taken from the list of drugs 
Kazakhstan. All costs were inflated to 2012 goda.Skidka of 3% and the horizon of 
life were considered. Results: Base-case analysis shows that the triple treatment 
(TVR + PR) than dual therapy (PR) leads to increased costs, and the best results. The 
results were robust when analyzing multiple sensitivity. The discount rate seemed to 
have a great impact. ConClusions: Telaprevir triple therapy for previously treated 
patients with HCV-genotype 1, more efficient than the dual therapy, but it leads to 
increased costs (in particular, the cost of medications).
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objeCtives: To estimate the costs of once-daily fixed dose combination (FDC) 
abacavir/lamivudine (ABC/3TC) compared with twice-daily combination of its 
individual components (ABC+3TC) and twice-daily FDC zidovudine/lamivudine 
(ZDV/3TC) in efavirenz (EFV)-based regimens for treatment-naïve adults with HIV 
infection in Russia. Methods: An Excel based model was developed to estimate the 
costs over 48- and 96-week time horizon for three compared regimens. Probabilities 
of switching to alternative and 2d line therapy due to low adherence and side effects 
were estimated for each regimen based on literature search. Costs of antiretroviral 
determinant of wasted doses was the number of children arriving. Depending 
on whether the clinic setting was urban/ rural, or outreach/fixed center, median 
session sizes varied between 5-13 children. Vaccine wastage added significant 
cost due to variations in session size even when modeled using a low multidose 
vial strategy. For instance, open vial waste from pneumococcal delivered in 5-dose 
presentation contributed $20MM in waste to Ugandan 10-year program costs. 
Results for each country and the impact session size distributions will be pre-
sented. ConClusions: Our analysis of field data confirmed significant session 
size variation within/across country immunization settings. Given challenges in 
mandating session sizes, pressures on vaccine budgets and high value of vaccine 
delivery, policy makers must consider new solutions to reduce the impact of waste 
on total program costs.
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objeCtives: To estimate the budget impact of the inclusion of ceftaroline com-
pared to linezolid or vancomycin on the top of complicated skin and soft tissues 
infections treatment scheme with antimicrobials according to Russian health care 
system. Methods: The budget impact analysis was conducted. Direct expenses 
associated with complicated skin and soft tissues infections and resulting follow-up 
costs were calculated using general tariff agreement of Russian obligatory insurance 
system and official national statistics. For reference, accepted exchange rate was 1 
EUR = 40 RUB. Results: Ceftaroline inclusion into the standard complicated skin 
and soft tissues infections therapy provided cost saving benefits compared with 
inclusion of linezolid or vancomycin in the complicated skin and soft tissues infec-
tions standard therapy scheme. Total health care costs of complicated skin and soft 
tissues infections therapy were approximately 77 997 RUB (1 950 EUR) per patient 
in ceftaroline group (therapy duration – 9 days), 78 816 RUB (1 970 EUR) per patient 
in vancomycin group (therapy duration – 10 days) and 117 893 RUB (2 947 EUR) per 
patient in linezolid group (therapy duration – 12 days). Treatment of complicated 
skin and soft tissues infections using standard therapy with ceftaroline inclusion 
compared to one with vancomycin or linezolid leads to cost savings of 819 RUB (20 
EUR) or 39 896 RUB (997 EUR) per patient, respectively. ConClusions: The results 
of budget impact analysis illustrate that including ceftaroline into the standard 
therapy of complicated skin and soft tissues infections in comparison with vanco-
mycin or linezolid has potential to reduce Russian health care system total costs 
for complicated skin and soft tissues infections treatment.
PIN25
esTImaTINg The CosT ImPaCT of swITChINg fRom a vIal To a PRe-fIlled 
syRINge mode of admINIsTRaTIoN foR The dTaa-IPv-hIB ‘5-IN-1’ vaCCINe 
IN INfaNTs
Kumar G.1, Padhiar A.1, Carroll S.2, Woods B.1, Shread K.2
1Oxford Outcomes Ltd., Oxford, UK, 2Sanofi Pasteur MSD, Maidenhead, UK
objeCtives: To estimate the cost impact to the NHS of switching from vial and 
syringe (V&S) to pre-filled syringe (PFS) administration of the ‘5-in-1’ vaccine for 
diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b. Methods: 
A model was developed to estimate the cost impact of the switch in children less 
than 2 years old. Vaccines supplied were assumed to reach three destinations: 
administered (an estimate of 785,320 primary courses); opened and not adminis-
tered (assumed to account for 7% of V&S and 0% of PFS supplied); or not opened 
by the expiry date (assumed to account for 0% of supply). All vaccines accrued 
acquisition and storage costs. PFS has bulkier packaging, leading to higher stor-
age costs. Administered vaccines incurred costs for staff time, consumables (only 
required for V&S) and potential needlestick injuries (assumed not to occur with 
PFS). As prices paid for vaccines by the NHS are not disclosed, the cost of a single 
dose was assumed equal for PFS and V&S. Appointment times were obtained from 
a survey of 200 nurses, which estimated that PFS saved on average 4 minutes 47 
seconds relative to V&S across three doses. All unit costs were sourced from the 
literature. Results: The introduction of PFS was estimated to save £7.91 per 3-dose 
primary course and £6,214,562 per year for the NHS. Reductions in wastage and 
staff time contributed the greatest savings. Varying the wastage rate from 1-10% 
resulted in total cost savings of £3-8million; investigation into better estimates 
of vial wastage would strengthen the results. All other sensitivity analyses had 
a minimal impact on results. ConClusions: The switch to PFS administration 
is estimated to have generated substantial cost-savings to the NHS. PFS has the 
potential to improve the efficiency of immunisation programmes by simplifying 
vaccine delivery and reducing the risk of handling errors.
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objeCtives: To assess the cost-effectiveness of pegylated interferons alfa-2a 
and alfa-2b combined with ribavirin in the treatment of Russian patients with 
chronic hepatitis C and identify potential budget impact considering the indica-
tor of rational drug use (IRDU). Methods: The pharmacoeconomic model was 
developed based on the data from randomized controlled trial MIST (M. Rumi 
et al., 2010). The cost-effectiveness ratios (CERs) for different patient subgroups 
were expressed as costs of medicines per one patient with sustained virologic 
response. 24- and 48-week time frames were used for patients with genotypes 2/3 
and 1/4, respectively. To assess quantitatively the impact of pharmaceutical form 
and recommended dose regimens, the IRDU was used. One-way sensitivity analy-
ses (SAs) were performed to investigate the robustness of the cost-effectiveness 
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for both groups. One-to-one propensity score matching (PSM) was used to compare 
health care costs and utilizations during the follow-up period between the HCV 
and comparison groups, adjusting for baseline demographic and clinical charac-
teristics. Results: Eligible patients (N= 270,752) were identified for the HCV and 
comparison cohorts. After applying 1:1 PSM matching, a total of 107,953 patients 
were matched from each group and baseline characteristics were well-balanced. 
HCV patients were more likely to be hospitalized (15.90% vs. 3.19%, p< 0.01) and 
report more emergency room (20.36% vs. 8.17%, p< 0.01), physician office (99.18% 
vs. 61.06%, p< 0.01), outpatient (99.25% vs. 61.84%, p< 0.01) and pharmacy visits 
(91.11% vs. 63.13%, p< 0.01) which resulted in higher health care costs for inpatient 
($5,284 vs. $911, p< 0.01), emergency room ($237 vs.$76, p< 0.01), outpatient ($4,673 
vs. $1,760, p< 0.01), physician office ($4,247 vs. $1,560, p< 0.01), pharmacy ($889 vs. 
$460, p< 0.01) and total costs ($10,846 vs. $3,131, p< 0.01) for HCV patients relative 
to the comparison group. ConClusions: Patients diagnosed with HCV were more 
likely to report higher health care utilization and were associated with a higher 
economic burden compared to the matched controls.
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objeCtives: : Pertussis (whooping cough) is a highly contagious bacterial disease. 
Infants in the first few months of life are particularly vulnerable with the highest 
reported rate of pertussis, risk of severe disease and deaths. Although, vaccina-
tion coverage rates have reached record-high levels in the United States (US), vac-
cine timeliness remains an issue. Methods: Using data from the 2010 National 
Immunization Survey (NIS), we estimated the vaccination timeliness for DTaP vac-
cines in US infants. A previously published static model accounted for the reduction 
of incidence of pertussis by vaccination according to a strict adherence to the ACIP 
vaccination schedule. The annual numbers of pertussis cases prevented in infants 
and the associated costs avoided from a health care system perspective were esti-
mated. Results: From the NIS dataset, the mean age at DTaP vaccination was 
76.3, 147.4 and 223.9 days, which means that on average each vaccination was in 
average delayed by 16.3, 27.4 and 43.9 days (with delays accumulating over time), 
respectively. The model predicted 3052 pertussis cases annually in infants < 1 year 
of age in the US. Applying a strict adherence to the vaccination schedule, approxi-
mately 313 cases of pertussis, 112 hospitalisations and 1 death could be avoided 
each year. This translates into savings of 57 QALYs and $1.3 million of costs to the 
health care system. ConClusions: Although previous publications have presented 
the number of cases avoided by timely vaccination, to our knowledge this is the 
first one to present the associated costs. Administering vaccines on time not only 
avoids cases but may also have a significant impact on quality of life and costs. 
These costs avoided may be redirected to developing tools and/or infrastructure to 
improve the vaccine timeliness of infants in future. Further research is needed to 
better understand the role of vaccination timeliness and completion.
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objeCtives: To analyse the antibiotic consumption pattern in hospital acquired 
pneumonia (HAP) patients in a tertiary care teaching hospital Methods: A pro-
spective observational study, carried out in a tertiary care teaching hospital from 
January 2011 to December 2012. HAP patients who fulfill the inclusion criteria were 
identified and enrolled into the study after taking informed consent. Patients were 
followed from the day of diagnosis of HAP, till the day of discharge or death. Patient 
data like demography (age, sex), antimicrobial agents used (dose, duration of treat-
ment), length of hospital stay and clinical outcome were recorded in a predesigned 
data collection form. The cost of antimicrobial therapy was recorded from the day 
of admission till the day of discharge. Antibiotic consumption was calculated using 
defined daily dose (DDD) methodology. Results: Total 310 patients were included 
in the study. Among study population 229 (73.9%) patients were male and mean age 
was 55.9±18.4 (mean±SD). Out of 310 patients 218 were improved, 37 were worsened 
or discharged against medical advice and 55 were expired. Mean length of hospi-
talization was 9.45±6.75 (mean±SD) days. Total 27 antimicrobial agents were used 
for the treatment pneumonia among these patients. Among these antimicrobial 
agents, consumption (DDD/100 bed days) was highest for piperacillin-tazobactum 
(parenteral, 0.12) followed by ceftriaxone (parenteral, 0.10), azithromycin (oral, 0.10) 
and trimethoprim-sulphamethoxazole (oral, 0.08). The percentage of treatment suc-
cess was highest among patients treated with piperacillin-tazobactum+macrolide 
combination (10%) followed by cephalosopin+macrolide combination (8%). 
However the cost of treatment was high for piperacillin-tazobactum+macrolide 
regimen ConClusions: This study provides estimate of quantities of differ-
ent antimicrobial agents used in the treatment of hospital acquired pneumonia. 
Piperacillin-tazobactum (parenteral) is highest consumed among 27 antimicrobial 
agents. Since percentage of treatment success is almost similar for piperacillin-
tazobactum+macrolide combination (10%) and cephalosopin+macrolide combina-
tion (8%), use of cephalosopin+macrolide combination should be encouraged in 
susceptible patients considering the lesser cost.
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drugs in the 1st and 2d line of therapy and routine follow-up costs were calculated 
based on prices of state procurements in the framework of national project of HIV 
prevention and the tariffs of the Russian health care system in 2012. One-way sen-
sitivity analysis was performed. Results: ABC/3TC+EFV is not associated with 
more costs vs ABC + 3TC + EFV regimen and even saves approximately 3390.60 rub 
(€ 80.30) per patient over 96 weeks of treatment. The sensitivity analysis showed that 
ABC/3TC FDC remains to be cost saving compared with ABC+3TC as long as the its 
package price is less than 6564.17 rub (€ 155.46) while keeping other model param-
eters unchanged. Still ABC/3TC+EFV is 28% more expensive than ZDV/3TC+EFV, 
though more effective and safe treatment option: the difference in costs vs 
ABC/3TC+EFV is 45267.05 rub. (€ 1,072.05) per patient over 96 weeks. ConClusions: 
FDC ABC/3TC may be considered as a more efficient and convenient treatment 
option than its monocomponents combination for first-line antiretroviral therapy 
of HIV patients in Russia. FDC ABC/3TC is more expensive versus ZDV/3TC, but the 
difference in costs seems appropriate for more safe and convenient alternative.
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objeCtives: To explore new patient pathways using a chlamydia/gonorrhoea point of 
care nucleic acid amplification test (POC NAAT), and estimate and compare the costs 
of the new pathways with the current pathways using standard laboratory-based 
NAAT testing in the UK. Methods: Consensus building activities were conducted 
with four sexual health clinics in the UK. They were selected through purposeful 
sampling to reflect a wide range of service delivery. Current pathways in which a 
chlamydia/gonorrhoea test was used were mapped out, and then new pathways 
using a POC NAAT were constructed. The consensus pathways were then costed using 
a patient pathway model built in Excel, and the cost of the current and POC NAAT 
pathways compared. Results: Pathways using a POC NAAT for asymptomatic and 
symptomatic patients and chlamydia/gonorrhoea only tests were shorter and less 
expensive than most of the current pathways (average savings of £4-8 for sympto-
matic and asymptomatic screening pathways if the POC NAAT costs £18/test). Patients 
that are tested using the POC NAAT can be treated on the same day, thus saving costs 
compared to patients who are treated at a subsequent appointment. ConClusions: 
A POC NAAT could be introduced to services and reduce current costs, and may mean 
more appropriate and quicker care for positive patients.
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objeCtives: In Ukraine immunization by age conducts against 10 infectious 
diseases: tuberculosis, hepatitis B (HBV), diphtheria, pertussis, tetanus, polio, 
Haemophilus influenzae, measles, rubella, mumps .The Law of Ukraine from 
21.10.2009 N 1658-VI approved the Program of immunization and protection against 
infectious diseases during 2009-2015.During the years 2011-2012 the media incor-
rectly submitted data on the results of vaccination and many parents refused vac-
cination and as a result there were about 12,000 cases of measles and rubella, it’s 
80 times more than in previous years. On State program of vaccination in 2010 
was allocated 237 mln UAH (1 USD= 7.99 UAH), in 2011 - 237 mln, in 2012 - 302 mln 
UAH. Methods: We conducted a cost per 1,000 children aged 0 to 1 years. Direct 
costs were calculated for vaccine Pentaxim (Sanofi Pasteur) which combined vac-
cine against hepatitis B (ukrainian producer “Biolik”) and was compared the costs 
for vaccine Infanrix hexa (GSK). We included the vaccine costs, the loss during 
storage, and the costs of medical personnel for vaccination. We used the prices 
from the ukrainian electronic pricing database “MORION” on 01.06.2012. Analysis of 
evidence-based data has shown that Pentaxim is equal clinical efficacy of Infanrix 
hexa, but increases the rate of vaccination coverage against hepatitis B. Results: 
The costs for Pentaxim and HiB vaccine were 633 240 UAH and costs of medical 
personnel (pediatrics, nurses) were 36763 UAH. The costs using vaccine Infanrix 
hexa were 803880 UAH, the costs of medical personnel – 18 381 UAH, respec-
tively. ConClusions: In 2012, 385 116 children vaccinated by Infanrix hexa and 
general costs were 118 307 590 UAH vs 363 000 children by Pentaxim were 95 830 
447 UAH. The results shown the need additional 22477143 UAH, which is justified 
to increase vaccination coverage against hepatitis B by 6%.
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objeCtives: To examine the economic burden and health care utilizations of the 
hepatitis C virus (HCV) in the U.S. veteran population. Methods: A retrospec-
tive database analysis was performed using the Veterans Health Administration 
Medical SAS datasets 01OCT2008-30SEP2012). Patients diagnosed with HCV 
(International Classification of Disease 9th Revision Clinical Modification [ICD-
9-CM] codes 070.41, 070.44, 070.51, 070.54, v02.62) were identified, and the first 
diagnosis date served as the index date. A comparator group was created by iden-
tifying patients without HCV but with the same age, region, gender and index year, 
and matching them by baseline Charlson Comorbidity Index. The index date for 
the comparator group was randomly chosen to reduce selection bias. A 1-year 
continuous health plan enrollment period pre- and post-index date was required 
